1
|
Parsanathan R. Copper's dual role: unravelling the link between copper homeostasis, cuproptosis, and cardiovascular diseases. Hypertens Res 2024; 47:1440-1442. [PMID: 38467792 DOI: 10.1038/s41440-024-01636-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2024] [Accepted: 02/18/2024] [Indexed: 03/13/2024]
Abstract
This graphic depicts the interplay between copper homeostasis and cuproptosis and their role in cardiovascular diseases. Copper is vital for cardiac mitochondrial function, while its dysregulation induces cuproptosis via Ferredoxin1 (FDX1) and lipoic acid synthase (LIAS). Cuproptosis is linked to myocardial ischemia/reperfusion injury, heart failure, atherosclerosis, and arrhythmias. Copper deficiency impacts atherosclerosis markers. Therapeutic interventions include copper chelators (e.g., ammonium tetrathiomolybdate), and oxidative phosphorylation inhibitors like elesclomol and copper ionophores (CuII(atsm), CuII(gtsm), and disulfiram). These interventions modulate intracellular copper, elevate NO, and reduce inflammatory cytokines, contributing to decreased cardiovascular diseases.
Collapse
Affiliation(s)
- Rajesh Parsanathan
- Department of Biotechnology, School of Integrative Biology, Central University of Tamil Nadu, Neelakudi, Thiruvarur, 610005, Tamil Nadu, India.
| |
Collapse
|
2
|
Cai L, Tan Y, Holland B, Wintergerst K. Diabetic Cardiomyopathy and Cell Death: Focus on Metal-Mediated Cell Death. Cardiovasc Toxicol 2024; 24:71-84. [PMID: 38321349 DOI: 10.1007/s12012-024-09836-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Accepted: 01/27/2024] [Indexed: 02/08/2024]
Abstract
Cardiac myocyte death is an essential initiator of the pathogenesis and progression of various etiological cardiomyopathies, including diabetic cardiomyopathy (DCM), a disease that has been reported since 1972. Cardiac cell death has been detected in the hearts of patients with diabetes and in animal models, and the role of cell death in the pathogenesis of DCM has been extensively investigated. The first review by the authors, specifically focusing on "Cell death and diabetic cardiomyopathy," was published in the journal, Cardiovascular Toxicology in 2003. Over the past two decades, studies investigating the role of cardiac cell death in the pathogenesis of DCM have gained significant attention, resulting in the discovery of several new kinds of cell death involving different mechanisms, including apoptosis, necroptosis, pyroptosis, autophagy, ferroptosis, and cuproptosis. After the 20th anniversary of the review published in 2003, we now provide an update with a focus on the potential role of metal-mediated cell death, ferroptosis, and cuproptosis in the development of DCM in compliance with this special issue. The intent of our review is to further stimulate work in the field to advance the body of knowledge and continue to drive efforts to develop more advanced therapeutic approaches to prevent cell death, particularly metal-dependent cell death, and, ultimately, to reduce or prevent the development of DCM.
Collapse
Affiliation(s)
- Lu Cai
- Department of Pediatrics, Pediatric Research Institute, University of Louisville School of Medicine, 570 S. Preston Street, Baxter I, Rm: 304F, Louisville, KY, USA.
- Wendy Novak Diabetes Institute, Norton Healthcare, Louisville, KY, USA.
- Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, USA.
- Radiation Oncology, University of Louisville School of Medicine, Louisville, KY, USA.
| | - Yi Tan
- Department of Pediatrics, Pediatric Research Institute, University of Louisville School of Medicine, 570 S. Preston Street, Baxter I, Rm: 304F, Louisville, KY, USA
- Wendy Novak Diabetes Institute, Norton Healthcare, Louisville, KY, USA
- Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, USA
| | - Brian Holland
- Division of Cardiology, Department of Pediatrics, Norton Children's Hospital, University of Louisville School of Medicine, Louisville, KY, USA
| | - Kupper Wintergerst
- Department of Pediatrics, Pediatric Research Institute, University of Louisville School of Medicine, 570 S. Preston Street, Baxter I, Rm: 304F, Louisville, KY, USA
- Wendy Novak Diabetes Institute, Norton Healthcare, Louisville, KY, USA
- Division of Endocrinology, Department of Pediatrics, Norton Children's Hospital, University of Louisville School of Medicine, Louisville, KY, USA
| |
Collapse
|